By combining MERFISH imaging with expansion microscopy, researchers have unlocked a new way to study bacteria at the ...

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment options.

The New Hampshire Department of Health and Human Services (DHHS) said a person from Merrimack County has become the first ...

Researchers have succeeded in cultivating an ultra-small bacterial strain parasitizing archaea and classified it as new species and genus of Minisyncoccus archaeiphilus.

AIST researchers, in collaboration with JAMSTEC, Hokkaido University and Tohoku University, have succeeded in cultivating an ...

Our guts are home to trillions of bacteria, and research over the last few decades has established how essential they are to our physiology – in health and disease.

Emblaveo will be available in the third quarter of 2025 to treat patients with intra-abdominal infections, a common cause of sepsis in the intensive care unit.

CAMBRIDGE, MA AND PITTSBURGH, PA / ACCESSWIRE / 10, 2025 / Next Gen Diagnostics (NGD), a pioneer in the development of machine learning models for whol ...

Addresses the significant threat of antimicrobial resistance.

Our guts are home to trillions of bacteria, and research over the last few decades has established how essential they are to ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...